Mumm, J. B. et al. IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell 20, 781–796 (2011).
Qiao, J. et al. Targeting tumors with IL-10 prevents dendritic cell-mediated CD8+ T cell apoptosis. Cancer Cell 35, 901–915.e4 (2019).
Teijaro, J. R. et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340, 207 (2013).
Wilson, E. B. et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340, 202–207 (2013).
Perez-Ruiz, E. et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569, 428–432 (2019).
Bertrand, F. et al. Blocking tumor necrosis factor α enhances CD8 T-cell-dependent immunity in experimental melanoma. Cancer Res. 75, 2619–2628 (2015).
Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540–1554.e12 (2016).
Lu, C., Talukder, A., Savage, N. M., Singh, N. & Liu, K. JAK–STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. Oncoimmunology 6, e1291106 (2017).
Du, W.-Y. et al. Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice. Gastric Cancer 27, 971–985 (2024).
Zak, J. et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science 384, eade8520 (2024).
Mathew, D. et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science 384, eadf1329 (2024).
Debureaux, P. E., Arrondeau, J., Bouscary, D. & Goldwasser, F. Nivolumab combined with ruxolitinib: antagonism or synergy? Ann. Oncol. 29, 1334–1335 (2018).
Nijland, M. et al. Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma. Ann. Hematol. 97, 905–907 (2018).
Tolu, S. S. et al. Combination JAK inhibition and immune checkpoint blockade for the treatment of 9p amplified Lymphomas. Blood 144, 336 (2024).
Elli, E. M., Baratè, C., Mendicino, F., Palandri, F. & Palumbo, G. A. Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. Front. Oncol. 9, 1186 (2019).
Patel, M. R. et al. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models. Cancer Gene Ther. 26, 411–418 (2019).
Wang, S.-W. et al. AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway. Oncol. Rep. 32, 1991–1998 (2014).
Lee, S. et al. Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model. Oncotarget 9, 9776–9788 (2018).
Moskowitz, A. J. et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood 138, 2828–2837 (2021).
Govaerts, I., Jacobs, K., Vandepoel, R. & Cools, J. JAK/STAT pathway mutations in T-ALL, including the STAT5B N642H mutation, are aensitive to JAK1/JAK3 inhibitors. HemaSphere 3, e313 (2019).
Datta, J. et al. Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer. Gastroenterology 163, 1593–1612 (2022).
Qureshy, Z. et al. STAT3 activation as a predictive biomarker for ruxolitinib response in head and neck cancer. Clin. Cancer Res. 28, 4737–4746 (2022).
Tavallai, M., Booth, L., Roberts, J. L., Poklepovic, A. & Dent, P. Rationally repurposing ruxolitinib (Jakafi®) as a solid tumor therapeutic. Front. Oncol. 6, 142 (2016).
Wei, X.-H. & Liu, Y.-Y. Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy. Front. Pharmacol. 14, 1326281 (2024).
Van Den Neste, E. et al. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. Haematologica 103, 840–848 (2018).
Gillessen, S. et al. JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: final results of a phase II, open label, multicentre clinical trial (JeRiCHO). Eur. J. Haematol. 109, 728–735 (2022).
Kim, S. J. et al. Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. BMC Cancer 19, 1080 (2019).
Jardim, D. L., Goodman, A., de Melo Gagliato, D. & Kurzrock, R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell 39, 154–173 (2021).
Chan, T. A. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 30, 44–56 (2019).
Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016).
Weichselbaum, R. R. et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. USA 105, 18490–18495 (2008).
Benci, J. L. et al. Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade. Cell 178, 933–948.e14 (2019).
Shen, H. et al. Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling. Nat. Commun. 13, 5013 (2022).
Lee, H.-J. et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26, 207–221 (2014).
Karjalainen, R. et al. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood 130, 789–802 (2017).
Han, E. S. et al. Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer. Oncotarget 9, 24304–24319 (2018).
Reeves, P. M. et al. Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice. Oncotarget 8, 94040–94053 (2017).
Stevens, L. E. et al. JAK–STAT signaling in inflammatory breast cancer enables chemotherapy-resistant cell states. Cancer Res. 83, 264–284 (2023).
Hu, Y. et al. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC. Apoptosis 19, 1627–1636 (2014).
Landen, C. N. et al. Phase I and randomized phase II study of ruxolitinib with frontline neoadjuvant therapy in advanced ovarian cancer: an NRG oncology group study. J. Clin. Oncol. 42, 2537–2545 (2024).
Hurwitz, H. et al. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Invest. New Drugs 36, 683–695 (2018).
Escobar-Zarate, D., Liu, Y. P., Suksanpaisan, L., Russell, S. J. & Peng, K. W. Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors. Cancer Gene Ther. 20, 582–589 (2013).
Ghonime, M. G. & Cassady, K. A. Combination therapy using ruxolitinib and oncolytic HSV renders resistant MPNSTs susceptible to virotherapy. Cancer Immunol. Res. 6, 1499–1510 (2018).
Xu, L. et al. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels. Mol. Oncol. 12, 269–286 (2018).
Shen, M. et al. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. J. Exp. Clin. Cancer Res. 38, 149 (2019).
Chen, H. et al. Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma. Br. J. Haematol. 192, 568–576 (2021).
Cao, Y. et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J. Allergy Clin. Immunol. 146, 137–146.e3 (2020).
Kumar, A., Taghi Khani, A., Sanchez Ortiz, A. & Swaminathan, S. GM-CSF: a double-edged sword in cancer immunotherapy. Front. Immunol. 13, 901277 (2022).
Bayne, L. J. et al. Tumor-derived granulocyte–macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21, 822–835 (2012).
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G. & Bar-Sagi, D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21, 836–847 (2012).
Huseni, M. A. et al. CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep. Med. 4, 100878 (2023).
Adlung, L. et al. Protein abundance of AKT and ERK pathway components governs cell type-specific regulation of proliferation. Mol. Syst. Biol. 13, 904 (2017).
Ebisuya, M., Kondoh, K. & Nishida, E. The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity. J. Cell Sci. 118, 2997–3002 (2005).
Mostafavi, S. et al. Parsing the interferon transcriptional network and its disease associations. Cell 164, 564–578 (2016).
Baker, B. J., Akhtar, L. N. & Benveniste, E. N. SOCS1 and SOCS3 in the control of CNS immunity. Trends Immunol. 30, 392–400 (2009).
Cheemalavagu, N. et al. Predicting gene-level sensitivity to JAK–STAT signaling perturbation using a mechanistic-to-machine learning framework. Cell Syst. 15, 37–48.e4 (2024).
Vian, L. et al. JAK inhibition differentially affects NK cell and ILC1 homeostasis. Front. Immunol. 10, 2972 (2019).
Hoang, T. N. et al. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell 184, 460–475.e21 (2021).
Bronte, V. et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J. Clin. Invest. 130, 6409–6416 (2020).
Choi, J. et al. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One 9, e109799 (2014).
Carniti, C. et al. Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects. Clin. Cancer Res. 21, 3740–3749 (2015).
Kenderian, S. S. et al. Ruxolitinib prevents cytokine release syndrome after CART cell therapy without impairing the anti-tumor effect in a xenograft model. Blood 128, 652 (2016).
Mestre-Durán, C. et al. Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells. Front. Immunol. 13, 1045316 (2023).
He, K. et al. G-CSF/GM-CSF-induced hematopoietic dysregulation in the progression of solid tumors. FEBS Open. Bio 12, 1268–1285 (2022).
Wlassits, R., Müller, M., Fenzl, K. H., Lamprecht, T. & Erlacher, L. JAK-inhibitors—a story of success and adverse events. Open. Access. Rheumatol.: Res. Rev. 16, 43–53 (2024).
Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316–326 (2022).
Cohen, S. B. et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann. Rheum. Dis. 80, 304 (2021).
Bukali, L. et al. Transient JAK/STAT inhibition by ruxolitinib modulates malaria-specific CD4+ T cell responses and enhances recall immunity in volunteers experimentally infected with Plasmodium falciparum. Preprint at medRxiv https://doi.org/10.1101/2025.04.09.25325416 (2025).
Pai, C.-C. S. et al. Clonal deletion of tumor-specific T cells by interferon-γ confers therapeutic resistance to combination immune checkpoint blockade. Immunity 50, 477–492.e8 (2019).
Arias-Badia, M. et al. Sequential JAK inhibition enhances antitumor immunity after combined anti-PD-1 and anti-CTLA4. JCI Insight 10, e187921 (2025).
Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. Immunother. Cancer 6, 56 (2018).
Le, R. Q. et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23, 943–947 (2018).
Zi, F. M., Ye, L. L., Zheng, J. F., Cheng, J. & Wang, Q. M. Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: a case report. Medicine 100, e25786 (2021).
Pan, B. et al. PD-1 antibody and ruxolitinib enhances graft-versus-lymphoma effect without increasing acute graft-versus-host disease in mice. Am. J. Transplant. 21, 503–514 (2021).
Xu, N. et al. Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells. Biochem. Biophys. Res. Commun. 595, 54–61 (2022).
Leclercq, G. et al. Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. Oncoimmunology 11, 2083479 (2022).
Masucci, C. et al. Case report: avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination. Front. Oncol. 13, 1212638 (2023).
Dougan, M., Luoma, A. M., Dougan, S. K. & Wucherpfennig, K. W. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell 184, 1575–1588 (2021).
Huang, Z. et al. IFNAR1 signaling in NK cells promotes persistent virus infection. Sci. Adv. 7, eabb8087 (2021).
Cheng, L. et al. Type I interferons suppress viral replication but contribute to T cell depletion and dysfunction during chronic HIV-1 infection. JCI Insight 2, e94366 (2017).
Zhen, A. et al. Targeting type I interferon-mediated activation restores immune function in chronic HIV infection. J. Clin. Invest. 127, 260–268 (2017).
Wu, T. et al. The TCF1–Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci. Immunol. 1, eaai8593 (2016).
Cunningham, C. R. et al. Type I and type II interferon coordinately regulate suppressive dendritic cell fate and function during viral persistence. PLoS Pathog. 12, e1005356 (2016).
Huang, Z. et al. IL-27 promotes the expansion of self-renewing CD8 T cells in persistent viral infection. J. Exp. Med. 216, 1791–1808 (2019).
Lukhele, S. et al. The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity. Immunity 55, 2369–2385.e10 (2022).
Moseman, E. A., Wu, T., de la Torre, J. C., Schwartzberg, P. L. & McGavern, D. B. Type I interferon suppresses virus-specific B cell responses by modulating CD8+ T cell differentiation. Sci. Immunol. 1, eaah3565 (2016).
Ng, C. T. et al. Blockade of interferon β, but not interferon α, signaling controls persistent viral infection. Cell Host Microbe 17, 653–661 (2015).
Fallet, B. et al. Interferon-driven deletion of antiviral B cells at the onset of chronic infection. Sci. Immunol. 1, eaah6817 (2016).
Sammicheli, S. et al. Inflammatory monocytes hinder antiviral B cell responses. Sci. Immunol. 1, eaah6789 (2016).
Boukhaled, G. M. et al. Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy. Nat. Immunol. 23, 1273–1283 (2022).
Minn, A. J. & Wherry, E. J. Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling. Cell 165, 272–275 (2016).
Qiu, J. et al. Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction. Nat. Cancer 4, 43–61 (2023).
Jacquelot, N. et al. Sustained type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 29, 846–861 (2019).
Zhu, C. et al. Development and validation of an interferon signature predicting prognosis and treatment response for glioblastoma. Oncoimmunology 8, e1621677 (2019).
Silginer, M. et al. Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. Neuro Oncol. 19, 1338–1349 (2017).
Duarte, C. W. et al. Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS One 7, e29653 (2012).
Memon, D. et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell 42, 209–224.e9 (2024).
Shi, Y. et al. Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors. EMBO Rep. 26, 521–559 (2025).
Zemek, R. M. et al. Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice. Nat. Commun. 13, 4895 (2022).
Srivastava, S., Koch, M. A., Pepper, M. & Campbell, D. J. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J. Exp. Med. 211, 961–974 (2014).
Osokine, I. et al. Type I interferon suppresses de novo virus-specific CD4 TH1 immunity during an established persistent viral infection. Proc. Natl Acad. Sci. USA 111, 7409 (2014).
Dai, Y. et al. Humoral determinants of checkpoint immunotherapy. Nature 644, 527–536 (2025).